References
- Shaw PJ. Molecular and cellular pathways of neurodegeneration in motor neuron disease. J Neurol Neurosurg Psychiatry. 2005;76:1046–57.
- Brooks BR, Shodis KA, Lewis DH, Rawling JD, Sanjak M, Belden DS, . Natural history of amyotrophic lateral sclerosis. Quantification of symptoms, signs, strength, and function. Adv Neurol. 1995;68:163–84.
- Couratier P, Hugon J, Sindou P, Vallat JM, Dumas M. Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors. Lancet. 1993;341:265–8.
- Terro F, Lesort M, Viader F, Ludolph A, Hugon J. Antioxidant drugs block in vitro the neurotoxicity of CSF from patients with amyotrophic lateral sclerosis. Neuroreport. 1996;7:1970–2.
- Tikka TM, Vartiainen NE, Goldsteins G, Oja SS, Andersen PM, Marklund SL, . Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neuron disease. Brain. 2002;125:722–31.
- Sen I, Nalini A, Joshi NB, Joshi PG. Cerebrospinal fluid from amyotrophic lateral sclerosis patients preferentially elevates intracellular calcium and toxicity in motor neurons via AMPA/kainate receptor. J Neurol Sci. 2005;235:45–54.
- Iwasaki Y, Ikeda K, Shiojima T, Tagaya M, Kinoshita M. Amyotrophic lateral sclerosis cerebrospinal fluid is not toxic to cultured spinal motor neurons. Neurol Res. 1995;17: 393–5.
- Gredal O, Witt MR, Dekermendjian K, Moller SE, Nielsen M. Cerebrospinal fluid from amyotrophic lateral sclerosis has no effect on intracellular free calcium in cultured cortical neurons. Mol Chem Neuropathol. 1996;29:141–52.
- Spreux-Varoquaux O, Bensimon G, Lacomblez L, Salachas F, Pradat PF, Le Forestier N, . Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci. 2002;193:73–8.
- Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. (Review Article). 2010;48:629–41.
- Almer G, Teismann P, Stevic Z, Halaschek-Wiener J, Deecke L, Kostic V, . Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology. 2002;58:1277–9.
- Wilms H, Sievers J, Dengler R, Bufler J, Deuschl G, Lucius R. Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J Neuroimmunol. 2003;144:139–42.
- Tateishi T, Yamasaki R, Tanaka M, Matsushita T, Kikuchi H, Isobe N, . CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. J Neuroimmunol. 2010;222:76–81.
- Grundstrom E, Lindholm D, Johansson A, Blennow K, Askmark H. GDNF but not BDNF is increased in cerebrospinal fluid in amyotrophic lateral sclerosis. Neuroreport. 2000;11:1781–3.
- Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, Simmons Z, . A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology. 2009;72:14–9.
- van den Berghe W, van den Bosch L, Robberecht W. Glial cells potentiate kainate-induced neuronal death in a motoneuron-enriched spinal coculture system. Brain Res. 1998;807:1–10.
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995;57:289–300.
- Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci. 1996;16:4069–79.